{"id":"W4388448664","doi":"10.1016/j.euo.2023.10.008","title":"Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Western University","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Abiraterone acetate; Pembrolizumab; Internal medicine; Oncology; Cohort; Interquartile range; Adverse effect; Clinical endpoint; Androgen deprivation therapy; Cancer; Clinical trial; Androgen receptor; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002456536,0.0008941525,0.001129623,0.0003056862,0.0005855422,0.0008247183,0.0006978352,0.0007165055,0.00168441],"category_scores_gemma":[0.001435454,0.0004888116,0.001550429,0.0004050607,0.0003893263,0.0006022938,0.0004583481,0.001356244,0.0003401606],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001122514,"about_ca_system_score_gemma":0.001997364,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003107653,"about_ca_topic_score_gemma":0.005610295,"domain_scores_codex":[0.9991085,0.0003875296,0.00007916496,0.000171483,0.0001308661,0.0001224016],"domain_scores_gemma":[0.9989673,0.0001141943,0.0003261059,0.0001344206,0.00008145823,0.0003765679],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5217081,0.01669871,0.4100786,0.0006115078,0.004280325,0.0005114009,0.0004971198,0.001177061,0.01110988,0.0001948687,0.003559103,0.02957331],"study_design_scores_gemma":[0.1549024,0.1339984,0.6938723,0.0001596237,0.003142845,0.001079359,0.0004382077,0.001924039,0.002841388,0.0002075566,0.00734572,0.00008809358],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997012,0.001007108,0.0001160945,0.000107694,0.00002564206,0.0004915445,0.0008020465,0.000007395936,0.0004303377],"genre_scores_gemma":[0.9966568,0.0003867927,0.0002736388,0.0002137765,0.00006834254,0.0003312179,0.001722449,0.000003910752,0.000342969],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003107653,"threshold_uncertainty_score":0.01299155,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02421598996196259,"score_gpt":0.3315793593632952,"score_spread":0.3073633694013327,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}